



Healthcare Special Opportunities Fund

Management Report of Fund Performance

December 31, 2023

Class A units and Class U units of Healthcare Special Opportunities Fund

Healthcare Special Opportunities Fund

For the Year ended December 31, 2023

All figures are reported in Canadian dollars unless otherwise noted.

This management report of fund performance contains financial highlights but does not contain either the complete interim financial report or annual financial statements of the investment fund. You can get a copy of the financial statements at your request and at no cost, by contacting LDIC Inc. in one of the methods below.

Unitholders may contact LDIC Inc. to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure by calling 416-362-4141, by writing to us at 10 Alcorn Avenue, Suite 205, Toronto, ON, M4V 3A9 or by visiting our website at www.ldic.ca (email at info@ldic.ca), or SEDAR+ at www.sedarplus.ca.

Investment Objectives and Strategies

The Fund's investment objective is to provide holders of Units ("Unitholders") with long-term total return through distributions and capital appreciation of the Fund's investment portfolio (the "Portfolio") by investing in equity and debt securities of issuers that derive a significant portion of their revenue or earnings from medical and healthcare products and/or services. Such issuers may include, but will not be limited to, issuers operating in the following healthcare industry sub-sectors: (i) healthcare services, financials, and insurance; (ii) healthcare products and technology; (iii) healthcare facilities and real estate investment trusts; and (iv) retirement lifestyle, wellness and entertainment (collectively, the "Healthcare Issuers").

The Fund has been created to invest in an actively managed Portfolio comprised primarily of publicly traded issuers and private issuers that derive a significant portion of their revenue or earnings from medical and healthcare products and/or services. The Fund will be invested primarily in publicly traded healthcare equity securities (the "Public Portfolio"), but may also invest up to 20% of the Fund's total assets in private equity investments (the "Private Portfolio"). It is expected that the Public Portfolio will be comprised of securities of 20 to 30 large, mid, and small capitalization publicly-listed Healthcare Issuers based in developed markets.

Through the Private Portfolio, LDIC Inc. ("LDIC" or the "Manager") will seek to enhance returns by investing in "late-stage" private equity investments in healthcare and healthcare related businesses. "Late-Stage" means an investment in a revenue-generating or soon-to-be revenue-generating business that is expected to go public or achieve another liquidity event within 12 to 24 months following the initial investment. The goal of the Manager is to provide investors with exposure to a limited number of investments in the Private Portfolio that it believes have potential for significant upside because the Fund will be investing at "pre-Initial Public Offering" prices. The Fund expects to make Private Portfolio investments at a point where the capital will be used to grow revenues of the healthcare business investee company. The healthcare business investee company may then seek to raise additional capital in public markets, or in some instances consider a sale of the business to a strategic or financial buyer.

Risk

An investment in the Fund involves risks. Certain risk factors relating to the Fund and the Units are listed below. Additional risks and uncertainties not currently known to the Manager or Industry Advisor, or that are currently considered immaterial, may also impair the operations of the Fund. An investment in the Fund is appropriate only for investors who have the capacity to absorb a loss on their investment and who can withstand the effect of potentially having no distribution being paid in any period. As the value of the Units of the Fund will be based upon the value of the Portfolio, risks relating to the Portfolio will affect investors in the Fund. The following are certain risk factors and considerations related to the Fund which prospective investors should consider before purchasing Units:

- No assurance on achieving investment objective
- Loss of investment
- No guaranteed return
- Equity securities risk
- Illiquid securities and private securities
- Fluctuations in value of securities underlying portfolio
- Fluctuations in Net Asset Value
- Risk related to healthcare issuers
- Regulatory risk
- Risks related to healthcare issuers operating in the real estate sector
- Sensitivity to interest rate fluctuations
- Use of derivative instruments
- Portfolio concentration risk
- Reliance on the manager and industry advisor
- Trading at a discount and risks relating to redemptions
- Taxation of the Fund

Further details on these risks can be found in the Funds' prospectus filed on SEDAR+ at www.sedarplus.ca.

Result of Operations

For the year ended December 31, 2023, the Class A units increased in value from \$11.98 to \$12.03. The Class U units increased in value from \$14.83 CAD to \$14.93 CAD and showed a return of 2.4% for Class A and 2.7% for Class U.

The Class A units are listed for trading on the Toronto Stock Exchange under ticker symbol of MDS.UN. As at December 31, 2023, 93.1% of the fund was invested in healthcare, 4.3% of the fund invested in financial sector and 1.8% was in cash.

The Fund had a net gain on financial instruments of \$981,435 for the year ended December 31, 2023 compared to a net loss of \$4,685,977 for the prior year. The total operating expenses decreased in 2023 by \$144,300 mainly due to decreased management fees of \$264,461 in 2023 compared to management fees of \$418,249 in 2022. There was an increase in the net assets per unit of \$0.27 from operations for Class A, and an increase in net assets per unit of \$0.36 from operations for Class U for the year ended December 31, 2023. Overall, the Fund had an increase in Net Assets attributable to holders of redeemable units from operations of \$437,261.

Recent Developments

The year 2023 saw the gradual reduction in actions to combat the COVID pandemic. The pandemic has receded to a much less serious health system issue. The large backlog of surgical cases deferred during COVID is being tackled across the world. The pent-up demand for surgical services has normalized and health services are rebounding. The performance of the Fund in 2023 reflected increasing demand for many of the health products and services produced and distributed by the companies invested in by the Fund.

Our 16% weighting to cash at December 31, 2022 reflected our cautious stance while we await improved health investment opportunities. During 2023 we reinvested cash into large capitalization U.S. based health equities. By year-end 2023, cash had been reduced to 1.8% of the Fund.

We are witnessing a rapid growth in weight loss and diabetes treatments. The Fund is invested in Novo Nordisk and Eli Lilly, two of the leaders in this growing field of treatment. There are likely to be further products entering this market. As well the injectables are likely to be produced in pill form which will expand their addressable market.

We also favour firms with a close connection to overall spending growth in health care such as United Health Group, Stryker Corp and Becton Dickinson. These firms will directly benefit from higher volumes of health care for the population over the age of 75. This is the most rapidly growing cohort of the North American population due to expanded life expectancy.

Related Party Transactions

The Manager of the Fund is LDIC Inc. The Manager provides investment and administrative services to the Fund. In consideration for these services the Manager receives a fee based on a percentage of the Net Assets of the Fund calculated daily and payable monthly, as follows:

Class A - 1.25% per annum

Class U - 1.25% per annum

The Manager will receive a performance fee (the "Performance Fee") from the Fund in respect of investments in the Private Portfolio including, for the purpose of calculating the Performance Fee, securities of private issuers in the Private Portfolio that have become publicly traded and public securities received on the disposition of securities of a private issuer in the Private Portfolio. The amount of the Performance Fee shall be determined as of the date of disposition (the "Determination Date") for cash proceeds for each such investment. The Performance Fee in respect of each investment will be equal to 20% of the amount by which the cash proceeds of disposition exceed 106% of the Threshold Amount (as defined below) calculated on a cumulative annual basis plus applicable taxes. Where an investment is held for a portion of any year, the calculation of the required 106% return for that year is made on a partial year basis.

The Performance Fee shall be calculated and accrued daily and be paid upon each Determination Date; however, no Performance Fee shall be paid in respect of any dispositions of securities of private issuers in the Private Portfolio unless on the Determination Date the proceeds of disposition of the investment exceed 107% of the original book value of the investment (the "Threshold Amount").

As of December 31, 2023, the Manager of the Fund and certain Directors and Officers of the manager held a total of 296,226 Class A units of the Fund.

Management Fees

The Manager is entitled to be paid a management fee by the Fund at an annual rate of 1.25% of the NAV of the Fund, plus applicable taxes, provided that the management fee payable to the Manager shall not be paid in respect to assets of the Fund invested in the securities of any investment funds (including mutual funds) managed by the Manager or an affiliate of the Manager. The Management Fee payable to the Manager will be calculated and accrued daily and be payable monthly in arrears based on the average NAV for that month. The Management Fee will be paid in cash.

Financial Highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the year ended December 31, 2023 and for the past five periods ended December 31, as applicable. In the year a fund or a series is established, 'Period' represents inception to December 31 of that year. Per unit data is derived from the Fund's financial statements.

The Fund's Net Assets per unit ⁽¹⁾

	Class A					
	2023	2022	2021	2020	2019	2018
	\$	\$	\$	\$	\$	\$
Net Assets, beginning of year	11.98	13.81	13.61	13.33	11.62	10.69
Increase (decrease) from operations:						
Total revenue	0.14	0.14	0.14	0.14	0.12	0.13
Total expenses	(0.33)	(0.27)	(0.27)	(0.23)	(0.24)	(0.27)
Realized gains (losses) for the year	0.29	(0.20)	0.12	2.19	0.75	2.70
Unrealized gains (losses) for the year	0.17	(1.89)	(0.49)	(1.41)	1.27	(1.23)
Total increase (decrease) from operations ⁽²⁾	\$ 0.27	\$ (2.22)	\$ 0.48	\$ 0.69	\$ 1.90	\$ 1.33
From income (excluding dividends)	-	-	-	-	-	-
From dividends	-	-	-	-	-	-
From capital gains	-	-	-	(0.44)	-	-
Return of capital	(0.24)	(0.25)	(0.27)	-	(0.24)	(0.24)
Total annual distributions ⁽³⁾	(0.24)	(0.25)	(0.27)	(0.44)	(0.24)	(0.24)
	\$	\$	\$	\$	\$	\$
Net Assets, end of year	12.03	11.98	13.81	13.61	13.33	11.62

	Class U					
	2023	2022	2021	2020	2019	2018
	\$	\$	\$	\$	\$	\$
Net Assets, beginning of year	14.83	17.91	17.74	17.14	14.80	13.86
Increase (decrease) from operations:						
Total revenue	0.17	0.19	0.19	0.18	0.16	0.17
Total expenses	(0.39)	(0.34)	(0.82)	(0.26)	(0.21)	(0.44)
Realized gains (losses) for the year	0.36	(0.28)	2.42	2.69	1.05	3.67
Unrealized gains (losses) for the year	0.22	(2.38)	(2.59)	(3.13)	0.90	(2.15)
Total increase (decrease) from operations⁽²⁾	0.36	(2.81)	(0.80)	(0.52)	1.90	1.25
Distributions:						
From income (excluding dividends)	-	-	-	-	-	-
From dividends	-	-	-	-	-	-
From capital gains	-	-	(0.24)	-	-	-
Return of capital	(0.29)	(0.35)	-	(0.31)	(0.31)	(0.10)
Total annual distributions⁽³⁾	(0.29)	(0.35)	(0.24)	(0.31)	(0.31)	(0.10)
	\$	\$	\$	\$	\$	\$
Net Assets, end of year	14.93	14.83	17.91	17.74	17.14	14.80

(1) This information is derived from the Fund's audited annual financial statements.

(2) Net Assets and distributions are based on the actual number of units outstanding at the relevant time. The increase/decrease from operations is based on the weighted average number of units outstanding over the financial year.

(3) Distributions were paid in cash/reinvested in additional units of the Fund, or both

Ratios and Supplemental Data

	Class A					
	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Total Net Asset Value (\$) ⁽¹⁾	18,879,535	19,398,102	36,179,354	35,816,353	36,008,359	34,671,576
Number of units outstanding ⁽¹⁾	1,568,800	1,618,637	2,619,502	2,632,259	2,700,771	2,984,572
Management expense ratio ^{(2) (5)}	2.45%	2.04%	1.82%	1.53%	1.79%	2.05%
Management expense ratio before waivers or absorption ^{(2) (5)}	2.45%	2.04%	1.82%	1.53%	1.79%	2.05%
Management expense ratio excluding performance fees ⁽⁵⁾	2.45%	2.04%	1.87%	1.83%	1.78%	1.75%
Trading expense ratio ^{(3) (5)}	0.31%	0.19%	0.20%	0.26%	0.22%	0.29%
Portfolio turnover rate ⁽⁴⁾	68.13%	44.34%	40.85%	91.65%	62.00%	106.52%
Net Asset Value per share (\$)	12.03	11.98	13.81	13.61	13.33	11.62

	Class U					
	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Total Net Asset Value (\$) ⁽¹⁾	7,465	7,415	10,749	99,337	267,348	901,096
Number of units outstanding ⁽¹⁾	500	500	600	5,600	15,600	60,900
Management expense ratio ^{(2) (5)}	2.39%	2.04%	1.64%	1.34%	1.08%	2.59%
Management expense ratio before waivers or absorption ^{(2) (5)}	2.39%	2.04%	1.64%	1.34%	1.08%	2.59%
Management expense ratio excluding performance fees ⁽⁵⁾	2.39%	2.03%	1.85%	1.85%	0.45%	1.79%
Trading expense ratio ^{(3) (5)}	0.31%	0.19%	0.20%	0.26%	0.22%	0.29%
Portfolio turnover rate ⁽⁴⁾	68.13%	44.34%	40.85%	91.65%	62.00%	106.52%
Net Asset Value per share (\$)	14.93	14.83	17.91	17.74	17.14	14.80

(1) The information is provided for the period ended December 31 of the period(s) shown, as applicable.

(2) Management expense ratio is based on total expenses (excluding broker commissions and other portfolio transaction costs before income taxes) for the stated period and is expressed as an annualized percentage of daily average Net Asset Value during the year. The decision to waive and/or absorb management fees and operating expenses is at the discretion of the Manager. The practice of waiving and/or absorbing management fees and operating expenses may continue indefinitely or may be terminated any time without notice to shareholders.

(3) The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average Net Asset Value during the year.


(4) The Fund's portfolio turnover rate indicates how actively the Fund's portfolio advisor manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the year. The higher a Fund's portfolio turnover in a period, the greater the trading costs payable by the Fund in the year, and the greater the chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high turnover rate and the performance of the Fund.

(5) Percentages are annualized.

Past Performance

A) Annual Total Returns (%)

The performance information shown is based on Net Asset Value. The bar chart shows the investment fund’s performance in percentage terms of Class A and Class U of the Fund for the period ending December 31, 2023, and since inception to December 31, 2023.



(1) Returns for Class A and Class U, are from July 15, 2015 to December 31, 2015.

B) Annual Compound Returns

The table below shows the annual compound return of each class of units of the Fund, for each period indicated.

	Class A			Class U				
	Since Inception (July 15/15)	1 year	3 years	5 years	Since Inception (July 15/15)	1 year	3 years	5 years
Healthcare Special Opportunities Fund	4.7%	2.4%	-2.1%	2.9%	4.0%	2.7%	-3.6%	2.0%

Summary of Investment Portfolio as at December 31, 2023

Top 25 Investments as of December 31, 2023

	% of Funds Net Asset Value
1 Boston Scientific Corp.	7.8
2 Thermo Fisher Scientific Inc	6.5
3 Danaher Corp	6.4
4 Novo Nordisk A/S	6.2
5 Eli Lilly & Co.	6.1
6 HCA Healthcare Inc.	6.0
7 Intuitive Surgical Inc	5.9
8 Zoetis Inc	5.5
9 UnitedHealth Group Inc.	5.4
10 Stryker Corp.	5.3
11 Quid Home Medical Corp.	5.2
12 AstraZeneca PLC.	5.2
13 Becton Dickinson and Co.	4.8
14 Arthritis Innovation Corp.	4.6
15 Horizons High Interest Savings ETF	4.0
16 Vitalhub Corp.	3.3
17 Proxamama, Inc.	2.3
18 Damona Pharmaceuticals Inc.	2.1
19 Cash	1.8
20 Cairn Memory Care Opportunities Fund LP	2.8
21 Grey Wolf Animal Health Corp.	1.1
22 DRI Healthcare Trust	1.0
23 Investx Series 19-08	0.3
24 Fero International Inc.	0.3
25 Paume	0.3

Total Net Asset Value of the Fund as at December 31, 2023: \$18,887,000

As of December 31, 2023, all investments were only long positions.

Sector Mix	% of Funds Net Asset Value
Consumer Discretionary	1.1
Consumer staples	-
Financials	4.3
Health Care	93.1
Cash	1.8
Net Other Assets/Liabilities	(0.3)
	<hr/> 100.0 <hr/>

Geographic Mix	% of Funds Net Asset Value
Canada	25.3
Denmark	6.3
United Kingdom	5.3
United States of America	63.1
	<hr/> 100.0 <hr/>

Corporate Information

Corporate Address

LDIC Inc.
10 Alcorn Ave., Suite 205, Toronto, ON M4V 3A9
416-362-4141 info@ldic.ca
www.ldic.ca

Auditors

Ernst & Young LLP
EY Tower
100 Adelaide Street West
PO Box 1, Toronto, Ontario, M5H 0B3

Legal Counsel

Wildeboer Dellelce LLP
365 Bay Street, Suite 800, Toronto,
ON M5H 2V1